Timothy Connolly, MD
Pulmonary Disease · Houston, TXNPI 1396798153
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by GSK at 29.2% of the total. 2025 is the largest year on record at $312, 4.2 times the $75 reported in 2019. That places this record below the midpoint for pulmonary disease clinicians in TX, where the typical reported total is $1,976.
Across 51 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$286
- Boehringer Ingelheim$244
- Pulmonx Corporation$129
- Electromed, Inc.$104
- Insmed, Inc.$49
- Sanofi$42
- plus $124 from 5 others
Across 3 payments — averaging $4182.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pneumrx, Inc$13K
What the payments were for
- Food & beverage$979100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 14 | $286 |
| Boehringer Ingelheim | 11 | $244 |
| Pulmonx Corporation | 5 | $129 |
| Electromed, Inc. | 10 | $104 |
| Insmed, Inc. | 3 | $49 |
| Sanofi | 2 | $42 |
| Pfizer | 2 | $35 |
| Grifols USA, LLC | 1 | $29 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| Mylan Specialty L.p. | 1 | $19 |
| AstraZeneca | 1 | $14 |
How this compares
$979 in reported general payments places this provider in the 35th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 379 | $406,904 |
| Breo ElliptaFluticasone/Vilanterol | 506 | $307,911 |
| OfevNintedanib Esylate | 16 | $189,429 |
| Spiriva RespimatTiotropium Bromide | 113 | $97,828 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 15 | $91,779 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 64 | $40,479 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 67 | $39,155 |
| SymbicortBudesonide/Formoterol Fumarate | 74 | $29,907 |
| Advair HfaFluticasone Propion/Salmeterol | 31 | $20,370 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 116 | $17,614 |
| Incruse ElliptaUmeclidinium Bromide | 26 | $16,233 |
| DuleraMometasone/Formoterol | 27 | $15,202 |
| BreynaBudesonide/Formoterol Fumarate | 43 | $14,382 |
| Arnuity ElliptaFluticasone Furoate | 30 | $12,688 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 47 | $9,784 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $286 | $782,8911,008 claims |
| Boehringer IngelheimOfev, Spiriva Respimat | $244 | $287,257129 claims |
| PfizerOctagam, Paxlovid | $35 | $93,14629 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $14 | $70,385138 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Houston
- Nicola HananiaHouston$1.3M
- Sandeep SahayHouston$378K
- Zeenat SafdarHouston$291K
- Howard HuangHouston$194K
- Brandy McKelvyHouston$168K
- Alexander StadnykHouston$158K
- Lisa KopasHouston$120K
- Sandeep GuptaHouston$118K
- Roberto CasalHouston$113K
- Dileep PuppalaHouston$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.